您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Padnarsertib(KPT-9274)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Padnarsertib(KPT-9274)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Padnarsertib(KPT-9274)图片
CAS NO:1643913-93-2
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 610.63
Formula C35H29F3N4O3
CAS No. 1643913-93-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (163.8 mM)
Water: < 1 mg/mL
Ethanol: 100 mg/mL (163.8 mM)
Chemical Name (1Z,2E)-3-(6-aminopyridin-2-yl)-N-((5-(4-(4,4-difluoropiperidine-1-carbonyl)phenyl)-7-(4-fluorophenyl) benzofuran-2-yl)methyl)acrylimidic acid
Synonyms KPT9274; PAK4-IN-1; KPT-9274; PAK4-IN 1; KPT 9274; PAK4-IN1
SMILES Code OC(/C=C/C1=NC(N)=CC=C1)=N\CC2=CC3=CC(C4=CC=C(C(N5CCC(F)(F)CC5)=O)C=C4)=CC(C6=CC=C (F)C=C6)=C3O2
实验参考方法
In Vitro

In vitro activity: KPT-9274 interferes with PAK4 and NAD biosynthetic pathways resulting in reduction of G2/M transit as well as induction of apoptosis and decrease in cell invasion and migration in several human RCC cell lines. The inhibition of the PAK4 pathway by KPT-9274 attenuates nuclear β-catenin as well as the Wnt/β-catenin targets cyclin D1 and c-Myc


Kinase Assay: KPT-9274 is a non-competitive dual inhibitor of PAK4 and NAMP with an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.


Cell Assay: cell migration and invasion assays were performed using transwell chambers. For the transwell migration assay, 1.5×104 cells were seeded on top of the polycarbonate filters, and 0.6 ml of growth medium with DMSO or KPT-9274 (1μM and 5μM) was added to both the upper and lower wells. After incubation for 12 hours, the filters were swabbed with a cotton swab, fixed with methanol, and then stained with Giemsa solution. For the in vitro invasion assay, filters were coated with Matrigel, and 2.5×104 cells were seeded onto the Matrigel and incubated for 20 hours. The cells attached to the lower surface of the filter were counted under a light microscope (10× magnification).

In VivoKPT-9274 treatment of the 786-O (VHL-mut) human RCC xenograft model leads to dose-dependent inhibition of tumor growth with no apparent toxicity. It also shows remarkable anti-tumor activity in sub-cutaneous xenograft models of pancreatic ductal adenocarcinoma (PDAC) cell lines and cancer stem cells as a single agent. KPT-9274 possesses desirable PK properties and is well tolerated in mice with the absence of any signs of toxicity when 200 mg/kg daily is administered either intravenously or orally.
Animal model786-O (VHL-mut) human RCC xenograft mice model
Formulation & Dosage Formulated in 58% Polyvinylpyrrolidone K30 + 21% methyl cellulose + 21% Phospholipon 90G; 100 and 200 mg/kg; P.O.
References Mol Cancer Ther. 2016 Sep;15(9):2119-29.